Tumour Necrosis Factor-α Antagonists in the Management of Rheumatoid Arthritis in the ElderlyA Review of Their Efficacy and Safety

被引：0
|
作者：
Beáta J. Radovits
Wietske Kievit
Roland F. J. M. Laan
机构：
[1] Radboud University Nijmegen Medical Centre,Department of Rheumatology
来源：
Drugs & Aging | 2009年 / 26卷
关键词：
Rheumatoid Arthritis; Rheumatoid Arthritis Patient; Etanercept; Health Assessment Questionnaire Score; Simplify Disease Activity Index;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Rheumatoid arthritis (RA) is a chronic inflammatory disease that frequently affects people aged ≥65 years, causing significant impairment with pain and functional disability. Elderly RA patients have specific problems, including co-morbid diseases, numerous concomitant medications, greater number of damaged joints as a result of longer disease duration and often a more severe disease presentation in elderly-onset RA. These factors, together with an age-related decline in the immune defence mechanisms, make elderly patients more vulnerable.
引用
收藏
页码：647 / 664
页数：17
相关论文
共 50 条
  • [1] Tumour Necrosis Factor-α Antagonists in the Management of Rheumatoid Arthritis in the Elderly A Review of Their Efficacy and Safety
    Radovits, Beata J.
    Kievit, Wietske
    Laan, Roland F. J. M.
    [J]. DRUGS & AGING, 2009, 26 (08) : 647 - 664
  • [2] Safety of tumour necrosis factor-α antagonists
    Khanna, D
    McMahon, M
    Furst, DE
    [J]. DRUG SAFETY, 2004, 27 (05) : 307 - 324
  • [3] Safety of Tumour Necrosis Factor-α Antagonists
    Dinesh Khanna
    Maureen McMahon
    Daniel E. Furst
    [J]. Drug Safety, 2004, 27 : 307 - 324
  • [4] Effectiveness and safety of the treatment with tumour necrosis factor a antagonists in rheumatoid arthritis patients
    Mendoza, MA
    Aznárez, HN
    Hernández, MJR
    Ruiz, FJM
    [J]. MEDICINA CLINICA, 2005, 125 (01): : 35 - 36
  • [5] EFFICACY AND SAFETY OF TUMOUR NECROSIS FACTOR ALPHA INHIBITORS IN RHEUMATOID ARTHRITIS
    Baraza Cristina, Gomez
    Francisco Javier, Manero Ruiz
    Espasol Angela, Pecondon
    Mendoza Mercedes, Arenere
    Orbis Iciar, Casiamares
    Maria Jose, Rabanaque Hernandez
    [J]. ATENCION FARMACEUTICA, 2013, 15 (03): : 150 - 157
  • [6] Tumour necrosis factor-α blockers in rheumatoid arthritis -: Review of the clinical experience
    Richard-Miceli, C
    Dougados, M
    [J]. BIODRUGS, 2001, 15 (04) : 251 - 259
  • [7] Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-α antagonists
    Isaacs, John D.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (12) : 1463 - 1475
  • [8] An overview of economic evaluations for drugs used in rheumatoid arthritis -: Focus on tumour necrosis factor-α antagonists
    Bansback, NJ
    Regier, DA
    Ara, R
    Brennan, A
    Shojania, K
    Esdaile, JM
    Anis, AH
    Marra, CA
    [J]. DRUGS, 2005, 65 (04) : 473 - 496
  • [9] The Effect of Tumor Necrosis Factor-α Antagonists on Arterial Stiffness in Rheumatoid Arthritis: A Literature Review
    Dulai, Rajdip
    Perry, Mark
    Twycross-Lewis, Richard
    Morrissey, Dylan
    Atzeni, Fabiola
    Greenwald, Stephen
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2012, 42 (01) : 1 - 8
  • [10] Tumour Necrosis Factor a Antagonists in the Treatment of Rheumatoid Arthritis: An Immunological Perspective
    Meroni, Pier-Luigi
    Valesini, Guido
    [J]. BIODRUGS, 2014, 28 : S5 - S13
12345